US 11,779,619 B2
Oncolytic virus for expression of immune checkpoint modulators
Nathalie Silvestre, Ergersheim (FR); Michel Geist, Brumath (FR); Karola Rittner, Strasbourg (FR); Jean-Baptiste Marchand, Obernai (FR); and Christine Thioudellet, Strasbourg (FR)
Assigned to Transgene SA, Illkirch Graffenstaden (FR)
Filed by Transgene SA, Illkirch Graffenstaden (FR)
Filed on Dec. 23, 2019, as Appl. No. 16/725,485.
Application 16/725,485 is a continuation of application No. 15/325,562, granted, now 10,555,981, previously published as PCT/EP2015/066263, filed on Jul. 16, 2015.
Claims priority of application No. 14306153 (EP), filed on Jul. 16, 2014.
Prior Publication US 2020/0197457 A1, Jun. 25, 2020
Int. Cl. A61K 35/768 (2015.01); C07K 16/28 (2006.01); C12N 15/863 (2006.01); A61K 9/00 (2006.01); C07K 14/535 (2006.01); A61K 39/00 (2006.01); A61K 35/763 (2015.01); A61K 35/761 (2015.01); A61K 47/02 (2006.01); A61K 9/08 (2006.01); C12N 7/00 (2006.01); C12N 9/10 (2006.01); C12N 9/80 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 9/0019 (2013.01); C07K 14/535 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C12N 15/8636 (2013.01); C12Y 204/02009 (2013.01); A61K 9/08 (2013.01); A61K 35/761 (2013.01); A61K 35/763 (2013.01); A61K 47/02 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5256 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C12N 7/00 (2013.01); C12N 9/1077 (2013.01); C12N 9/80 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2799/023 (2013.01); C12Y 305/01023 (2013.01)] 21 Claims
 
1. An oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said virus is a vaccinia virus defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene and defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in only the viral I4L gene, and wherein said one or more immune checkpoint modulator(s) is selected from antibodies that specifically bind to PD-L1, PD-L2, LAG3, Tim3, BTLA, or CTLA4.